

# **Ravi A. Madan, M.D.**

## **Head, Prostate Cancer Clinical Research Section**

Genitourinary Malignancies Branch  
Center for Cancer Research,  
National Cancer Institute, NIH  
Bethesda, MD

## **Program Director**

Physician Scientist Early Investigator Program  
Center for Cancer Research,  
National Cancer Institute, NIH  
Bethesda, MD

Building 10, 13N240b  
10 Center Drive  
Bethesda, M  
(301) 480-7168  
madanr@mail.nih.gov

### **Curriculum Vitae Sections/Links:**

### **page**

- |  |          |
|--|----------|
| 1. <a href="#"><u>Positions and Training</u></a>     | RAM/CV2  |
| 2. <a href="#"><u>NIH Service Positions</u></a>      | RAM/CV2  |
| 3. <a href="#"><u>National Service Positions</u></a> | RAM/CV3  |
| 4. <a href="#"><u>Editor and Expert Reviewer</u></a> | RAM/CV4  |
| 5. <a href="#"><u>Clinical Research Activity</u></a> | RAM/CV4  |
| 6. <a href="#"><u>Invited Presentations</u></a>      | RAM-CV9  |
| 7. <a href="#"><u>Publications</u></a>               | RAM-CV16 |
| 8. <a href="#"><u>Book Chapters</u></a>              | RAM-CV28 |
| 9. <a href="#"><u>Honors and Awards</u></a>          | RAM-CV29 |
| 10. <a href="#"><u>Peer Review Activity</u></a>      | RAM-CV30 |

**Positions and Training**

<b>Head, Prostate Cancer Clinical Research Section</b>	<b>Genitourinary Malignancies Branch</b> <i>Center for Cancer Research,</i> National Cancer Institute, NIH Bethesda, MD	5/22-present
<b>Senior Clinician</b>	<b>Genitourinary Malignancies Branch</b> <i>Center for Cancer Research,</i> National Cancer Institute, NIH Bethesda, MD	12/18-present
<b>Clinical Director</b>	<b>Genitourinary Malignancies Branch</b> <i>Center for Cancer Research,</i> National Cancer Institute, NIH Bethesda, MD	1/14-3/22
<b>Staff Clinician</b>	<b>Genitourinary Malignancies Branch</b> <i>Center for Cancer Research,</i> National Cancer Institute, NIH Bethesda, MD	1/14-12/18
<b>Attending Oncologist</b>	<b>Walter Reed National Military Medical Center</b> Genitourinary Oncology Clinic Bethesda, MD	7/09-present
<b>Assistant Clinical Investigator</b>	<b>National Cancer Institute, NIH</b> Laboratory of Tumor Immunology and Biology & Medical Oncology Branch Bethesda, MD	7/09-12/13
<b>Postgraduate Training</b>	<b>National Cancer Institute, NIH</b> Bethesda, MD Oncology/Hematology Fellowship	7/05-6/09
	<b>East Orange VA Hospital</b> East Orange, NJ UMDNJ – University Hospital Internal Medicine Program Chief Medical Resident	7/04-6/05
	<b>Rutgers (UMDNJ) – University Hospital</b> Newark, NJ Internal Medicine Residency Program	7/01-6/04
<b>Education</b>	<b>Rutgers (UMDNJ) – New Jersey Medical School</b> Newark, NJ Doctor of Medicine	8/97-5/01
	<b>University of Michigan</b> Ann Arbor, MI B.S. in Biology and Economics	9/93-5/97

**NIH Service Positions**

National Cancer Institute Clinical Review Panel

2020-present

Reviewer, NIH Senior Leadership Program	2020-2021
Organizing Committee: NIH-AACR Cancer Autoimmunity Immunotherapy Meeting	2019-2020
Solid Tumor/Immunotherapy Fellows Research Review Committee	2018-present
Program Director: Physician Scientist Early Investigator Program, Center for Cancer Research, NCI (formerly Clinical Investigator Development Program).	2018-
NCI/SITC Immunotherapy Fellowship Committee	2016-present
Grant Reviewer: NCI Cancer Clinical Investigator Team Leadership Award	5/2014
Medical Oncology Clinical Competency Committee	9/11-present
Medical Oncology Fellowship Core Curriculum Committee	9/11-present
<b><u>National and International Service</u></b>	
2022 Screening RFA Peer Review Meeting – American Cancer Society	10/26/2022
Research Advisory Committee, Prostate Cancer UK	9/2021-(2024)
Member on the Oncologic Drugs Advisory Committee (ODAC) of the Food and Drug Administration	9/2021-(6/2025)
NRG Oncology Genitourinary Core Committee	2020-present
Ad-Hoc Reviewer, Department of Veterans Affairs (VA) Cooperative Studies Scientific Evaluation Committee (CSSEC)	2021-2022
Ad-Hoc Member, Oncologic Drugs Advisory Committee (FDA) – Review of Checkpoint Inhibitors in Bladder Cancer	4/28/21
Chair, Veteran’s Administration Precision Oncology Special Interest Panel.	2020-present
Chair, Veteran’s Administration Review Committee for Emergent COVID19 Studies	4-6/2020
Meeting Co-Chair: ASCO-SITC Pre-Annual Seminar on Immunotherapy	2019
Organizing Committee: ASCO-SITC Pre-Annual Seminar on Immunotherapy	2017-2018
Chair: 2018 ASCO Scientific Program Committee	2018
ASCO Scientific Program Committee for Annual Meeting	2016-2018
SITC Cancer Immunotherapy Guidelines Prostate Subcommittee	2016-present
Consultant to the Oncologic Drugs Advisory Committee (FDA)	2016-2021
ASCO Annual Meeting Auditor	2016-2019
Reviewer: ASCO Annual Meeting Education Book	2015-2016
Guest Expert Panelist: Medicare Advisory Committee Meeting on Activated Cellular	11/2010

**Editor and Expert Reviewer**

Grant Reviewer: Prostate Cancer Foundation (Challenge Awards)	2019-2023
Grant Reviewer: UCSF Benioff Initiative for Prostate Cancer Research	2019
Grant Reviewer: 2019 Prostate Cancer Research Program (PCRP) for the Department of Defense Congressionally Directed Medical Research Programs	2019
Grant Reviewer: German Federal Ministry of Education and Research	2019
Associate Editor, Clinical/Translational Oncology, <i>Journal of ImmunoTherapy of Cancer</i>	2018-present
Section Editor, Immuno-Oncology, <i>The Oncologist</i>	2018-present
Grant Reviewer: Swiss National Science Foundation	2018
Member, European Academy for Tumor Immunology	2016
Grant Reviewer: Dutch Cancer Society (KWF)	2016
Grant Reviewer: Cancer Research Wales (Velindre Cancer Centre, Cardiff, UK)	2015
Grant Reviewer: Prostate Cancer Foundation (Challenge Awards)	7/2012
Grant Reviewer: Prostate Action (United Kingdom)	2012, 2013 2016
Grant Reviewer: Department of Veterans Affairs Cooperative Studies Program (CSP)	1/2011
Grant Reviewer: Department of Veterans Affairs Merit Review Subcommittee for the Oncology (ONC A) Program	12/10-present

**Clinical Research Activity**

**Principal Investigator:** Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL (NCT05588128)

**Principal Investigator:** A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination with the Immunocytokine M9241 in Localized High and Intermediate Risk Prostate Cancer Treated with Androgen Deprivation Therapy (NCT05361798)

**Principal Investigator:** M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer (NCT0463352)

**Principal Investigator:** Radium-223 in Biochemically Recurrent Prostate Cancer (NCT04206319)

**Principal Investigator:** Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment (NCT03531827)

**Principal Investigator:** Combination Immunotherapy in Biochemically Recurrent Prostate Cancer (NCT03315871)

**Principal Investigator:** Phase II Trial of Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer (NCT03072160)

**Principal Investigator:** Docetaxel and Prostavac in Metastatic Castration Sensitive Prostate Cancer (NCT02649855)

**Principal Investigator:** Prostavac in Biochemically Recurrent Prostate Cancer (NCT02649439)

**Principal Investigator:** A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (NCT02616185) - site PI

**Principal Investigator:** A Randomized Phase II Study of L-BLP25 in Combination with Standard Androgen-Deprivation Therapy and Radiation Therapy for Newly Diagnosed, High-Risk Prostate Cancer Patients L-BLP25 in Prostate Cancer (NCT01496131)

**Principal Investigator:** A Randomized Phase II Trial Combining Vaccine Therapy with PROSTVAC /TRICOM and Enzalutamide vs. Enzalutamide Alone in Men with Metastatic Castration Resistant Prostate Cancer (NCT01867333)

**Principal Investigator:** A Phase II Trial of Enzalutamide in Combination with PSA-TRICOM in Patients with Non-metastatic Castration Sensitive Prostate Cancer (NCT01875250)

**Principal Investigator:** Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide (NCT02130700)

**Principal Investigator:** A Pilot study of recombinant yeast CEA vaccine in patients with recurrent medullary thyroid cancer (NCT01856920)

**Principal Investigator:** A Targeted Phase I/II trial of ZD6474 (Vandetanib CAPRELSA) Plus the Proteasome Inhibitor, Bortezomib (Velcade®), in Adults with Solid Tumors with a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (NCT00923247)

**Principal Investigator:** A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma (NCT00923130)

**Principal Investigator:** A Randomized Phase II Trial Combining Vaccine Therapy with PROSTVAC/TRICOM and Flutamide vs Flutamide Alone in Patients with Androgen-Insensitive, Nonmetastatic (D0.5) Prostate Cancer (NCT00450463)

**Principal Investigator:** An Open-Label Phase I Study to Evaluate the Safety and Tolerability of a Vaccine Consisting of Whole, Heat-Killed Recombinant *Saccharomyces cerevisiae* (Yeast) Genetically Modified to Express CEA Protein in Adults with Metastatic CEA-Expressing Carcinoma (NCT00924092)

**Principal Investigator:** A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer (NCT00942578)

**Principal Investigator:** A Phase II Trial of Docetaxel, Thalidomide, Prednisone, and Bevacizumab in Patients with Androgen-Independent Prostate Cancer (NCT00942578)

**Associate Investigator:** A Phase 1/2 open-label, multi-center, dose-escalation study of safety, tolerability, pharmacokinetics, dosimetry, and response to repeat dosing of <sup>177</sup>Lu-PSMA-R2 radio-ligand therapy in patients with prostate specific membrane antigen (PSMA) positive (68Ga-PSMA-R2) progressive metastatic castration-resistant prostate cancer, following previous systemic treatment.

**Associate Investigator:** Phase I/II Trial of Combination Immunotherapy in Subjects with Advanced HPV Associated Malignancies (NCT04287868)

Associate Investigator: Phase II Trial of Combination Immunotherapy in Subjects with Advanced Small Bowel and Colorectal Cancers

Associate Investigator: Phase I/II Trial of HPV Vaccine PRGN-2009 Alone or in Combination with Anti-PD-L1/TGF- $\beta$  trap (M7824) in Subjects with HPV Positive Cancers (NCT04432597)

Associate Investigator: A phase 1/2, open label, dose-escalation, safety and tolerability study of NC410 in subjects with advanced or metastatic solid tumors

Associate Investigator: A Feasibility Study Investigating the Use of Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Cancer Pain (NCT04442425)

Associate Investigator: Phase I/II trial investigating the safety, tolerability, pharmacokinetics, immune and clinical activity of SX-682 in combination with TriAdeno vaccine regimen and M7824 (TGF-b “trap”/PD-L1; Bintrafusp alpha) in advanced solid tumors (STAT) (NCI-20-C-0155)

Associate Investigator: A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer (NCT03976843)

Associate Investigator: A Phase II Study of Neoadjuvant Androgen Deprivation Therapy Combined with Enzalutamide and Abiraterone Using Multiparametric MRI and 18F-DCFPyL-PET/CT in Newly Diagnosed Prostate Cancer (NCT03860987)

Associate Investigator: Natural History Study of Men at High Genetic Risk for Prostate Cancer (NCT03805919)

Associate Investigator: A Phase 1/2 open-label, multi-center, safety and tolerability study of a single dose of 68Ga-PSMA-R2 in patients with biochemical relapse (BR) and metastatic prostate cancer (mPCa).

Associate Investigator: A Phase I/II study of immunotherapy combination BN-Brachyury vaccine, M7824, ALT-803 and Epacadostat (QuEST1) (NCT03493945)

Associate Investigator: Bicalutamide with or without metformin for biochemical recurrence in prostate cancer patients (BIMET-1) (NCT02614859)

Associate Investigator: Treatment of Patients with Castration Resistant Prostate Cancer using a Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines (NCT03481816)

Associate Investigator: A Bioequivalence Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer

Associate Investigator: A Pilot Study to Evaluate the Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men with Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females (NCT03436745)

Associate Investigator: Phase II Trial of M7824 in Subjects with HPV Associated Malignancies (NCT03427411)

Associate Investigator: An open-label Phase 1 trial to evaluate the safety and tolerability of a Modified Vaccinia Ankara (MVA) priming followed by fowlpox booster vaccines modified to express brachyury and T cell costimulatory molecules (MVA-BN-Brachyury/FPV-Brachyury) (NCT03349983)

Associate Investigator: Phase I Trial Using a Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer (NCT03384316)

Associate Investigator: A Feasibility Study of Mobile Sensor Technologies to Assess General Symptomology of Cancer Patients (NCT04465214)

Associate Investigator: 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer (NCT03181867)

Associate Investigator: Evaluation of 18F-DCFPyL PSMA- versus 18F-NaF-PET imaging for Detection of Metastatic Prostate Cancer (NCT03173924)

Associate Investigator: A Phase 1/2 Trial of CV301 in Combination with Nivolumab versus Nivolumab in Subjects with Previously Treated Non-Small Cell Lung Cancer (NCT02840994)

Associate Investigator: Phase I/II Study of PROSTVAC in Combination with Nivolumab and / or Ipilimumab in Men with Prostate Cancer (NCT02933255)

Associate Investigator: A Phase Ib Open Label, Dose Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination with M9241 (NHS-IL12) in Subjects with Locally Advanced, Unresectable, or Metastatic Solid Tumors (NCT02994953)

Associate Investigator: A Randomized Phase II trial of Standard of Care Alone or in Combination with Ad-CEA vaccine and Avelumab in Patients with Previously Untreated Metastatic Colorectal Cancer (NCT03050814)

Associate Investigator: A Pilot Clinical Trial of Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (NCT02788201)

Associate Investigator: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications (NCT02517398)

Associate Investigator: A Phase Ib, Dose Escalation, Multiple Dose Trial with HuMax-IL8 in Patients with Metastatic or Unresectable, Locally Advanced Malignant Solid Tumors (NCT02536469)

Associate Investigator: A Phase I Study of (Cabozantinib) plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and other Genitourinary Tumors (NCT02496208)

Associate Investigator: Phase I/II study of the anti-programmed death ligand-1 antibody MEDI4736 in combination with olaparib or cediranib for advanced solid tumors and advanced or recurrent ovarian, triple negative breast, lung, prostate and colorectal cancers (NCT02484404)

Associate Investigator: Neoadjuvant Androgen Deprivation and Enzalutamide: Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer (NCT02430480)

Associate Investigator: A Randomized, Double-Blind, Phase 2 Trial of GI-6301 (Yeast-Brachyury Vaccine) Versus Placebo in Combination with Standard of Care Definitive Radiotherapy in Locally Advanced, Unresectable, Chordoma (NCT02383498)

Associate Investigator: A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of MSB0010718C in Subjects with Merkel Cell Carcinoma (NCT02155647)

Associate Investigator: A Randomized, Placebo-Controlled Phase II Study of Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men with Stage D0 Prostate Cancer (NCT02362451)

Associate Investigator: A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA 1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer (NCT02203513)

Associate Investigator: A Pilot Study of 18F-DCFBC PET/CT in Prostate Cancer (NCT02190279)

Associate Investigator: A Phase II Study of Neoadjuvant rFowlpox-PSA (L155)-TRICOM (Prostvac-F/TRICOM) in Combination with rVaccinia-PSA (L155)-TRICOM (Prostvac-V/TRICOM) in Men with Prostate Cancer Undergoing Treatment with Radical Prostatectomy (NCT02153918)

Associate Investigator: Evaluation of Ferumoxytol Enhanced MRI for the Detection of Lymph Node Metastases in Genitourinary (Prostate, Bladder and Kidney) Cancers (NCT02141490)

Associate Investigator: A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus Calmette-Guerin (BCG) given in combination with PANVAC versus BCG given alone in Adults with High Grade Non-Muscle Invasive Bladder Cancer (NMIBC) who failed at least 1 Induction Course of BCG (NCT02015104)

Associate Investigator: Evaluation of Local Response of Prostate Cancer to Irradiation Using Multiparametric MRI and MR-Guided Biopsies (NCT01834001)

Associate Investigator: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of avelumab (MSB0010718C), a monoclonal anti-PD-L1 antibody, in subjects with metastatic or locally advanced solid tumors and expansion to selected indications (NCT01772004)

Associate Investigator: A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial Carcinoma (NCT01688999)

Associate Investigator: A Phase I Study of Cabozantinib (XL184) plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer (NCT01683994)

Associate Investigator: Lenalidomide Maintenance Therapy in Multiple Myeloma: A Phase II Clinical and Biomarker Study (NCT01675141)

Associate Investigator: NaF PET/CT Repeatability, Responsiveness, and Response Assessment in Patients with Metastatic Castrate-Resistant Prostate Cancer to Bone Treated with Either an Antimicrotubule Directed Agent or Androgen Receptor (AR)-Directed Therapy (NCT01516866)

Associate Investigator: A Phase II Study of AMG 386 and Abiraterone in Metastatic Castration Resistant Prostate Cancer (NCT01553188)

Associate Investigator: An Open Label Phase I Study to Evaluate the Safety and Tolerability of GI-6301 Vaccine Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (yeast) Genetically Modified to Express Brachyury Protein in Adults with Solid Tumors (NCT01519817)

Associate Investigator: A Randomized, Double-blind, Phase III Efficacy Trial of PROSTVAC-V/F ± GM-CSF in Men with Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer PROSTVAC-V/F in Prostate Cancer (NCT01322490)

Associate Investigator: First In-Human Phase I Trial of NHS-IL12 in Patients with Metastatic Solid Tumors (NCT01417546)

Associate Investigator: A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients with Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors (NCT01352962)

Associate Investigator: A Phase I/II Study of TRC105 in Metastatic Castrate-Resistant Prostate Cancer (CRPC) (NCT01090765)

Associate Investigator: A Phase II trial of Bevacizumab, Lenalidomide, Docetaxel and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer (NCT00942578)



Associate Investigator: A Pilot Study of Vaccination with Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer (NCT02362464)

Associate Investigator: Talactoferrin in Treating Patients with Stage IIIB or Stage IV Non-Small Cell Lung Cancer (NCT00923741)

Associate Investigator: A Randomized, Placebo-Controlled Phase II Trial of Limited Gonadotropin-Releasing Hormone Agonist Therapy with or without Vaccine (Onyvax) in Patients with D0 Prostate Cancer (NCT00514072)

Associate Investigator: A Randomized Phase 2.5 Study of 153Sm-EDTMP (Quadramet) with or without a PSA TRICOM Vaccine in Patients with Androgen-Insensitive Metastatic Prostate Cancer (NCT00450619)

Associate Investigator: A Randomized Pilot Phase II Study of Docetaxel Alone or in Combination with PANVAC-V (Vaccinia) and PANVAC-F (Fowlpox) in Patients with Metastatic Breast Cancer (NCT00179309)

Associate Investigator: Phase I Trial of a PSA-Based Vaccine and an Anti-CTLA-4 Antibody in Patients with Metastatic Androgen-Independent Prostate Cancer (NCT00113984)

Associate Investigator: A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Prostate Cancer Patients with Local Failure Following Radiotherapy or Clinical Progression on Androgen-Deprivation Therapy in the Absence of Local Definitive Therapy (NCT00096551)

Associate Investigator: An Open-Label Pilot Study to Evaluate the Safety and Tolerability of PANVAC<sup>TM</sup>-V (Vaccinia) and PANVAC<sup>TM</sup>-F (Fowlpox) in Combination with Sargramostim in Patients with Metastatic Carcinoma: Ovarian Cancer and Breast Cancer-Specific (NCT00088413)

### Invited Presentations

“Quality in the Context of Quantity: Evaluating Treatment Intensification” ASCO Annual Meeting, Poster Discussion Session, Chicago, IL.	6/3/23
“Current Challenges in Prostate Cancer: PSMA PET & Accurately Defining “Neuroendocrine” Prostate Cancer. PRIMO Meeting, Honolulu, HI.	2/24/23
“Immuno-Cytokines in Prostate Cancer.” Therapeutic Focus: Immuno Oncology (Virtual)	11/28/22
“Emerging (Potential) Role of Cytokines in Prostate Cancer.” 5 <sup>th</sup> Annual Global Summit on Genitourinary Malignancies, Banff, Canada	11/11/22
“Evaluating Biochemical Recurrence with Rising PSA.” 5 <sup>th</sup> Annual Global Summit on Genitourinary Malignancies, Banff, Canada	11/10/22
“Management of Oligometastatic Prostate Cancer.” ESMO 2022 Colorado (Denver, CO)	10/16/22
“Treatment of Advanced Prostate Cancer.” 1st Annual INOVA GU Cancer Seminar: Advances in Prostate Cancer, Fairfax, VA	5/6/22
“Immunotherapy in Bladder Cancer – Current Status” PRIMO: Practical Recommendations for Immuno and Molecular Oncology, Waikola, Hawaii	2/18/22
“Beyond Immune Checkpoint Inhibition: Developing Tumor Targeted Immunocytokine Strategies in Prostate Cancer” Hamon Center for Therapeutic Oncology Research & Simmons Comprehensive Cancer Center Experimental Therapeutics Program Invited Lecture (UT Southwestern. Virtual)	1/6/22

---

“Can Immunocytokines Optimize the Prostate Cancer Immune Microenvironment?” Prostate Cancer UK’s Webinar Series: Spotlight on... (Virtual)	10/28/21
“Immunocytokines as a Means to Optimize Immunotherapy in Prostate Cancer” Next-Gen Cytokine Therapeutics Summit 2021 (Virtual)	9/22/21
“Introducing Immunocytokines to the Prostate Cancer Microenvironment” Immuno Week (Virtual)	7/8/2021
“New Immunotherapeutic Approaches to Advanced Prostate Cancer” Medstar Advances in the Management of Prostate, Bladder and Kidney Cancers – 2021 (Virtual)	6/18/21
“Next Gen Immunotherapy Strategies in Prostate Cancer: Can Immunocytokines Succeed where PD1/PDL1 Inhibitors Have Not?” Massachusetts General Hospital Oncology Grand Rounds (Virtual)	5/13/21
“Seeking synergy: The evolution of I/O strategies in combination with radiation” NRG: GU Research Strategy Retreat (Virtual)	3/12/21
“Bladder Cancer: Sequencing Therapeutic Choices” PRIMO: Practical Recommendations for Immuno and Molecular Oncology (Virtual)	2/11/21
“Immunocytokine-based Combination Strategies in Prostate Cancer” Biomarkers Series and Immuno Series (Virtual)	10/16/20
“Immunocytokine Strategies with Radiation in Prostate Cancer” CHI Immuno-Oncology Virtual Summit	10/8/20
“What is next for Immunotherapy?” (Panel Chair) CHI Immuno-Oncology Virtual Summit	10/8/20
Session Chair: Immunotherapy, 13 <sup>th</sup> Annual Prostate Cancer Retreat	3/1/20
Session Chair: Oral Abstract Session, 2020 ASCO-SITC Clinical Immuno-Oncology Symposium, Orlando, FL	2/6/20
“Bladder Cancer: Where does immunotherapy fit in?” PRIMO: Practical recommendations in Immuno & Molecular Oncology Meeting, Honolulu, Hawaii	2/1/20
“Immunotherapy Strategies in Biochemically Recurrent Prostate Cancer” 4th International Prostate Cancer and Urologic Oncology Symposium, New York, NY.	11/7/19
Session Chair: CAR-T and Directed T-cell Therapy: Advancing Beyond B-ALL AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	10/27/19
“Prostate Cancer: An Overview” Congressional Men’s Health Caucus Prostate Cancer Taskforce, Washington, DC.	9/25/19
“Immunocytokine Strategies in Prostate Cancer.” Immuno-Oncology Summit, Boston, MA	8/8/19
“Next Generation Immunotherapy Strategies in Prostate Cancer.” Cedars Sinai Oncology Grand Rounds, Los Angeles, CA	8/5/19
“GU Oncology Clinical Update” Washington Hospital Center Medicine Grand Rounds, Washington, DC	5/31/19

---

“ImmunoOncology Treatments for Prostate Carcinoma: Future Directions” Reggio Calabria, Italy	4/13/19
“Immunotherapy Strategies in Prostate Cancer“ John Fitzpatrick Irish Genitourinary Cancer Conference 2019, Dublin, Ireland	4/5/19
“GU Cancer Case Discussions.” HemOnc Today New York: Immunotherapy and Targeted Therapies, New York, NY	3/21/19
“Rising PSA: When to Pull the Trigger?” HemOnc Today New York: Immunotherapy and Targeted Therapies, New York, NY	3/21/19
“Metastatic Prostate Cancer Therapies.” HemOnc Today New York: Immunotherapy and Targeted Therapies, New York, NY	3/21/19
“Renal Cell Cancer: Is Immunotherapy Front-Line Again?” Practical Recommendations in Immuno and Molecular Oncology (PRIMO), Maui, HI	2/1/19
“Bladder Cancer: Where does Immunotherapy Fit In? Practical Recommendations in Immuno and Molecular Oncology (PRIMO), Maui, HI	2/1/19
“Combination Immunotherapy Strategies” 3rd International Prostate Cancer and Urologic Oncology Symposium, New York, NY.	12/13/18
“Immunotherapy and Prostate Cancer” 3rd International Prostate Cancer and Urologic Oncology Symposium, New York, NY.	12/13/18
“Immunotherapy and Targeted Agents for Prostate Cancer” Chemotherapy Foundation Symposium, New York, NY	11/7/2018
“Moving Forward with Immunotherapy in GU Malignancies” Global Summit on Genitourinary Malignancies, Banff Canada	11/1/2018
“Best of ASCO 2018: Genitourinary Malignancies (Prostate Cancer)” Best of ASCO, Washington, DC	8/3/2018
“Immune-Based Combinations with Standard Cytotoxic Therapies in Prostate Cancer.” Prostate Cancer UK: Immunology Frontier Meeting, London, UK.	6/26/2018
“The Perils of Immunologic Heterogeneity.” Prostate Cancer Foundation Coffey-Holden Prostate Cancer Academy, Los Angeles, CA.	6/23/2018
“Immunotherapy in Prostate Cancer: The Path Forward.” ASCO Annual Meeting Cancer Immunotherapy Today: Maximizing Patient Outcomes, Chicago, IL	6/3/2018
Session Chair, “Winds of Change” ASCO 2018 Annual Meeting Patient Outcomes, Chicago, IL	6/3/2018
“Case Studies in Immune Related Adverse Events.” ASCO Annual Meeting Pre-Meeting Seminar, Chicago, IL	6/1/2018
Session Chair. ASCO -Pre Meeting Cancer Immunotherapy Today: Maximizing	6/1/2018
“Immune Checkpoint Inhibitors for Prostate Cancer.” Korean World Urologic Congress at American Urologic Association Annual Meeting, San Francisco, CA	5/20/2018

---

“Developing Immunotherapy Strategies in Biochemically Recurrent Prostate Cancer.” American Urologic Association Annual Meeting, San Francisco, CA	5/18/2018
“Optimizing the Immune Microenvironment in Prostate Cancer.” MaidStone Life Sciences: 8th Annual Cancer Immunotherapy Conference, New York, NY	4/5/2018
“Vaccine Strategies for Immunoprevention.” NCI Cancer Prevention ISCORE Meeting Shady Grove, MD	3/22/18
“Case Studies in Bladder Cancer.” HemOnc Today New York 2018, New York, NY	3/3/2018
“Case Studies in Prostate Cancer.” HemOnc Today New York 2018, New York, NY	3/2/2018
“What’s New in Prostate Cancer?” HemOnc Today New York 2018	3/2/2018
“Prostate Cancer: The Next Horizon in ImmunoOncology.” 2018 Genitourinary Malignancies Symposium Ancillary Educational CME Event. San Francisco, CA	2/8/2018
“Immunotherapy in Prostate and Bladder Cancer.” Annual PRIMO Meeting, Maui, HI	2/2/2018
“Clinician Case Study in Immunotherapy - Prostrate Cancer.” Immuno-Oncology Frontiers, Miami, FL	1/24/2018
“Developing Cancer Vaccine-based Treatment Strategies.” An International Multidisciplinary Meeting on NSCLC under the Siege of Immunotherapy, Reggio Calabria, Italy	11/3/2017
“Emerging Concepts in Cancer Immunotherapy” PERI: Cancer Pathophysiology, Current Therapies, Clinical Trials and Drug Development, Washington, DC.	10/27/2017
“Prostate Cancer Clinical Update” PERI: Cancer Pathophysiology, Current Therapies, Clinical Trials and Drug Development, Washington, DC.	10/27/2017
“FDA Panel Discussion on Prostate Cancer” White Oak, MD.	10/25/2017
“Developing Immunotherapy for Medullary Thyroid Cancer.” MEN Syndrome Symposium, Bethesda, MD.	10/20/2017
“Promising Immune Checkpoint Inhibitor Combination Studies in Prostate Cancer” 24th Annual Prostate Cancer Foundation Scientific Retreat, Washington, DC	10/5/2017
“Rationale and Opportunities for Immunotherapy in the (Neo)Adjuvant Setting” Immuno-Oncology Summit 2017, Boston, MA	8/30/2017
“MRI Imaging Changes following Immunotherapy in Patients with Prostate Cancer” Next Generation Dx Summit, Washington, DC	8/17/2017
“Radium-223 as an Immunomodulator—ongoing studies with Checkpoint Inhibition” Prostate Cancer Foundation: 2017 Coffey-Holden Prostate Cancer Academy Meeting, Carlsbad, CA	6/16/2017
Session Chair, Prostate Cancer Oral Abstract Session, ASCO Annual Meeting, Chicago, IL	6/3/2017
“Immunotherapy Strategies for Prostate Cancer” Emory University, Atlanta, GA	5/11/2017
“Developing Immunotherapeutic Strategies for Prostate Cancer” Fox Chase Cancer Center, Philadelphia, PA	5/3/2017

“Developing Immunotherapy and Biomarkers in Prostate Cancer: Challenges and Strategies” Thirteenth Annual Biomarkers & Immuno-Oncology World Congress, Philadelphia, PA	5/3/2017
“Combination Immunotherapy and Radiation-based Therapy in Prostate Cancer” Bayer Life Science Workshop, Baltimore, MD	3/30/2017
ASCO SITC Immunotherapy Poster Walk Leader	2/2017
“Treatment Challenges in Castrate-Resistant Prostate Cancer: Choosing and Sequencing Therapy.” Practical Recommendations in Immuno and Molecular Oncology (PRIMO) Meeting, Maui, HI	2/11/2017
“Bladder Cancer: Opportunities and Innovations With Immunotherapy.” Practical Recommendations in Immuno and Molecular Oncology (PRIMO) Meeting, Maui, HI	2/11/2017
“Review of Immunotherapy Strategies and Clinical Trials for Prostate Cancer.” The 9th W.B. Ingalls Memorial Prostate Health & Cancer Symposium, Boca Raton, FL	1/28/2017
“Emerging Concepts in Cancer Immunotherapy.” Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development, Washington, DC	10/20/2016
“Prostate Cancer Clinical Update.” Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development, Washington, DC	10/20/2016
“Proposed Radium 223 trials in Prostate Cancer.” Scientific Working Group Meeting on Radium-223, New York, NY	9/9/2016
“Developing Therapeutic Cancer Vaccine Strategies for Prostate Cancer” Immuno-Oncology Summit, Boston, MA	8/31/2016
“Developing Rational Vaccine Combination Therapies in Cancer.” Nanovaccine Initiative Annual Meeting, Ames, Iowa.	5/23/2016
“Immunotherapy Strategies for Prostate Cancer” PCF Young Investigator Lecture Series (webinar)	4/16/2016
“Developing Immunotherapy Strategies for the Treatment of Prostate Cancer” Cedars Sinai Visiting Professor Lecture.	1/14/2016
“Treatment Challenges in Castrate Resistant Prostate Cancer: Choosing and Sequencing Therapy.” Practical Recommendations in Immuno and Molecular Oncology (PRIMO) Meeting, Maui, HI	1/11/2016
“Integrating Therapeutic Cancer Vaccines into Treatment for Prostate Cancer. Vaccines R&D-2015, Baltimore, MD	11/3/2015
“Cancer Vaccines: Establishing a Fully-Personalised Cancer Treatment.” Cancer Vaccines: Advancing Immuno-oncology, London, England	9/16/2015
“Immunotherapy strategies for the treatment of Prostate Cancer” 13th UAA Congress 2015 (Urological Association of Asian and Chinese Urological Association) Shanghai, China	9/5/2015
“Clinical Experience with Immune Combinations in Prostate Cancer” IMVACS Immunotherapy and Vaccine Cancer Summit, Boston, MA.	8/25/2015

---

“Emerging Concepts in Prostate Cancer Immunotherapy” Webcast, Cancer Research Institute	5/29/2015
“Immunotherapy as Personalized Medicine” 8th Immunotherapeutics & Immunomonitoring Conference, San Diego, Ca.	1/26/2015
“Prostate Cancer Immunotherapy: Lessons Learned” Center for Cancer Research Grand Rounds, National Cancer Institute, Bethesda, MD	1/9/15
“Prostate Cancer Vaccine (PROSTVAC) For Prostate Cancer Prevention” Immune Response Modulation for Cancer Prevention, Shady Grove, MD	11/10/14
“Prostate Cancer Immunotherapy” University of Nebraska, Omaha	9/24/14
“Integrating Immunotherapy into Prostate Cancer Treatment” Education Session, ASCO Annual Meeting, Chicago, IL	6/3/14
“The Emerging Role of Immunotherapy in the Treatment of Cancer” Grand Rounds Virginia Hospital Center , Arlington, VA	4/25/14
“Immunotherapy in Oncology: Understanding The Kinetics of Responses.” Cancer Immunotherapy, A Long Awaited Reality. New York, NY	3/27/14
Session Chair, ASCO GU “Prostate Cancer- Current Role of Immunotherapy in the Clinic” Symposium, San Francisco, CA	1/30/14
“Potential Influence of Therapeutic Cancer Vaccines on Tumor Growth Rates and the Clinical Implications” VIC Congress: Immunotherapies, Brussels, Belgium	12/4/13
“Treating Cancer in the Age of Modern Immunotherapy” Cancer Vaccines Conference, London, England.	9/18/13
“The Growing Understanding of the Clinical Impact of Therapeutic Cancer Vaccines” NCI’s Center of Excellence in Immunology Lecture Series, Bethesda, MD.	6/18/13
“Therapeutic Cancer Vaccines in the Treatment of Prostate Cancer: Current Understanding and Future Directions.” Oncology Grand Rounds, Washington Hospital Center, Washington, DC	6/14/13
“Abiraterone in the Treatment of Metastatic Prostate Cancer: Current Understanding, Future Directions” ASCO Genitourinary Cancers Symposium – Best of Journals, Orlando, FL	2/15/13
“Modern Immunotherapy: Current Understanding, Future Strategies.” Vaccine Forum: Phacilitate's Vaccine Forum, Washington, DC	1/30/13
“Therapeutic Cancer Vaccines in the Treatment of Prostate Cancer: Emerging Treatment Strategies.” Oncology Grand Rounds Stony Brook University Medical Center, Stony Brook, NY	12/13/12
“Understand the Impact of Immunotherapy: Current and Future Paradigms.” Chemotherapy Foundation Symposium, New York, NY	11/9/12
“Enhancing Standard and Emerging Therapies with Therapeutic Cancer Vaccines” Medical Oncology Grand Rounds, Walter Reed National Military Medical Center, Bethesda, MD	9/27/12
“A Yeast-Based Therapeutic Cancer Vaccine Targeting CEA (GI-6207); Results of a	3/12/12

Phase I Study.” CTEP Early Drug Development Spring Meeting, Rockville, MD	
“Clinical Trial Strategies for Deploying Modern Immunotherapies as Monotherapies or in Combinations.” Molecular Molecular Medicine Tri-Conference 2012, San Francisco, CA	2/23/12
“Making Progress without Delaying Progression: Understanding the Delayed Benefits of Therapeutic Cancer Vaccines.” 9 <sup>th</sup> Vaccines Discovery and Development: All Things Considered, Boston, MA.	11/7/11
“Therapeutic Cancer Vaccines Combined with Standard Therapies in the Treatment of Human Carcinoma.” NIH Research Festival: Advances in Immune Targeted Therapies, Bethesda, MD.	10/24/11
“Current and Emerging Therapies in Prostate Cancer.” Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development, Washington, DC.	10/18/11
“Prostate Cancer.” Cancer 101: A Basic Overview of Current Therapies for New Oncology Researchers, Arlington, VA.	7/19/11
“Novel Strategies in the Design and Development of Recombinant Vaccines for Cancer Therapy.” 9 <sup>th</sup> International Symposium on Targeted Anticancer Therapies, Paris, France.	3/9/2011
“Translating Cancer Vaccines from the Laboratory to the Clinic.” National Institutes of Health Clinical Center Grand Rounds, Bethesda, MD.	3/2/2011
“Incorporating Modern Immunotherapy into Clinical Practice and Clinical Trial Design.” 8 <sup>th</sup> Cancer Drugs in Research and Development Conference: Novel Cancer and Immuno Therapeutics Summit, San Diego, CA.	1/27/2011
“Immunotherapy for Prostate Cancer: Explaining the Conundrum of Improved Survival without Improvement in Time to Progression.” Immunotherapeutics and Vaccine Summit, Boston, MA.	8/17/2010
“Lessons Learned from Anti-CTLA-4 Therapy in Prostate Cancer.” Prostate Cancer Foundation – NCI Treatment Sciences Meeting, Bethesda, MD.	4/6/2010
“Protocol Concept: Intermittent Chemotherapy with Therapeutic Cancer Vaccine.” Cancer and Leukemia Group B 2010 Spring Committee Meetings: GU Malignancies, Raleigh, NC.	3/18/2010
“Talactoferrin & Saccharomyces cerevisiae–CEA in the Treatment of Lung Cancer.” 10 <sup>th</sup> Annual Targeted Therapies of the Treatment of Lung Cancer, Santa Monica, CA.	2/25/10
“Therapeutic Cancer Vaccines: Changing Paradigms in Prostate Cancer.” 7 <sup>th</sup> Annual Cancer Drugs Research and Development Conference, San Diego, CA.	1/29/2010
“Prostate Cancer Clinical Update. Cancer: Pathophysiology, Current Therapies, Clinical Trials, and Drug Development.” Pharmaceutical Education and Research Institute, Washington, DC.	4/2/2009
“Therapeutic Cancer Vaccines for Prostate Cancer.” UT–Southwestern CMC Conference, Dallas, TX.	12/18/2008
“Vector-Based Vaccines in the Treatment of Prostate Cancer.” University of Wisconsin Oncology Conference, Madison, WI.	11/18/2008

- “Prostate Cancer Immunotherapy.” Fox Chase Cancer Center, Lippincott Conference, Philadelphia, PA. 10/29/2008
- “Prostate Cancer Immunotherapy.” Georgetown University Oncology Grand Rounds, Washington, DC. 10/27/2008
- “Overall Survival Analysis of a Phase II Study Using a Poxviral-Based Vaccine, PSA-TRICOM, in the Treatment of Metastatic, Castrate-Resistant Prostate Cancer.” 2008 American Society of Clinical Oncology Annual Meeting, Chicago, IL. 5/31/2008
- “Novel Immune Therapies for Prostate Cancer.” Medical Grand Rounds, East Orange Veterans Hospital, East Orange, NJ. 4/20/2007
- “Bone Health After the Diagnosis of Prostate Cancer.” American Urologic Association: Living with Prostate Cancer, Linthicum, MD. 9/30/2006

**Publications**

1. Redman JM, O'Sullivan Coyne G, Reed CT, **Madan, RA**, Strauss J, Steinberg SJ, Marte J, Cordes L, Heery C, Gulley JL. Avelumab in Patients With Metastatic Colorectal Cancer. *Oncologist*. 2023.
2. Phelps TE, Harmon SA, Mena E, Lindenberg L, Shih JH, Citrin DE, Pinto PA, Wood BJ, Dahut WL, Gulley JL, **Madan, RA**, Choyke PL, Turkbey B. Predicting Outcomes of Indeterminate Bone Lesions on (18)F-DCFPyL PSMA PET/CT Scans in the Setting of High-Risk Primary or Recurrent Prostate Cancer. *J Nucl Med*. 2023;64(3):395-401.
3. **Madan, RA**, Redman JM, Karzai F, Dahut WL, Cordes L, Fakhrejehani F, Vu T, Sheikh N, Schlom J, Gulley JL. Avelumab in Men With Metastatic Castration-Resistant Prostate Cancer, Enriched for Patients Treated Previously With a Therapeutic Cancer Vaccine. *J Immunother*. 2023;46(4):145-51.
4. **Madan, RA**, Bilusic M, Stein MN, Donahue RN, Arlen PM, Karzai F, Plimack E, Wong YN, Geynisman DM, Zibelman M, Mayer T, Strauss J, Chen G, Rauckhorst M, McMahon S, Couvillon A, Steinberg S, Figg WD, Dahut WL, Schlom J, Gulley JL. Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer. *Oncologist*. 2023.
5. Gatti-Mays ME, Tschernia NP, Strauss J, **Madan, RA**, Karzai FH, Bilusic M, Redman J, Sater HA, Floudas CS, Toney NJ, Donahue RN, Jochems C, Marte JL, Francis D, McMahon S, Lamping E, Cordes L, Schlom J, Gulley JL. A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors. *Oncologist*. 2023;28(4):364-e217.
6. Cordes LM, Karzai F, Figg WD, **Madan, RA**. Relugolix in Clinical Practice: The Best Route for All? *Oncologist*. 2023.
7. Autio KA, Higano CS, Nordquist L, Appleman LJ, Zhang T, Zhu XH, Babiker H, Vogelzang NJ, Prasad SM, Schweizer MT, **Madan, RA**, Billotte S, Cavazos N, Bogg O, Li R, Chan K, Cho H, Kaneda M, Wang IM, Zheng J, Tang SY, Hollingsworth R, Kern KA, Petrylak DP. First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC). *J Immunother Cancer*. 2023;11(3).
8. Atiq MO, Pastor DM, Karzai F, Hankin AR, Turkbey B, Cordes LM, Brownell I, Liu Y, Chesnut GT, **Madan, RA**. First-line pembrolizumab plus androgen deprivation therapy for locally advanced microsatellite instability-high prostate cancer in a patient with Muir-Torre syndrome: A case report. *Front Oncol*. 2023;13:1126476.



9. Atiq M, Chandran E, Karzai F, **Madan, RA**, Aragon-Ching JB. Emerging treatment options for prostate cancer. *Expert Rev Anticancer Ther.* 2023;23(6):625-31.
10. Schmidt KT, Karzai F, Bilusic M, Cordes LM, Chau CH, Peer CJ, Wroblewski S, Huitema ADR, Schellens JHM, Gulley JL, Dahut WL, Figg WD, **Madan, RA**. A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide. *Oncologist.* 2022;27(9):718-e694.
11. Phelps TE, Harmon SA, Mena E, Lindenberg L, Shih JH, Citrin DE, Pinto PA, Wood BJ, Dahut W, Gulley JL, **Madan, RA**, Choyke PL, Turkbey B. Predicting Outcomes of Indeterminate Bone Lesions on (18)F-DCFPyL PSMA PET/CT Scans in the Setting of High-Risk Primary or Recurrent Prostate Cancer. *J Nucl Med.* 2022.
12. Parsons JK, Pinto PA, Pavlovich CP, Uchio E, Nguyen MN, Kim HL, Gulley JL, Sater HA, Jamieson C, Hsu CH, Wojtowicz M, House M, Schlom J, Donahue RN, Dahut WL, **Madan, RA**, Bailey S, Centuori S, Bauman JE, Parnes HL, Chow HS. A Phase 2, Double-blind, Randomized Controlled Trial of PROSTVAC in Prostate Cancer Patients on Active Surveillance. *Eur Urol Focus.* 2022.
13. **Madan, RA**, Mena E, Lindenberg L, Choyke PL. With New Technology Comes Great Responsibility: Prostate-Specific Membrane Antigen Imaging in Recurrent Prostate Cancer. *J Clin Oncol.* 2022;40(26):3015-9.
14. Lee S, Elton DC, Gulley JL, Pickhardt PJ, Dahut WL, **Madan, RA**, Pinto PA, Citrin DE, Summers RM. Assessment of Aortoiliac Atherosclerotic Plaque on CT in Prostate Cancer Patients Undergoing Treatment. *Tomography.* 2022;8(2):607-16.
15. Kase AM, Tan W, Copland JA, 3rd, Cai H, Parent EE, **Madan, RA**. The Continuum of Metastatic Prostate Cancer: Interpreting PSMA PET Findings in Recurrent Prostate Cancer. *Cancers (Basel).* 2022;14(6).
16. Karzai F, **Madan, RA**. Deciphering the enigma of neuroendocrine prostate cancer. *J Clin Invest.* 2022;132(21).
17. Fourquet A, Rosenberg A, Mena E, Shih JJ, Turkbey B, Blain M, Bergvall E, Lin F, Adler S, Lim I, **Madan, RA**, Karzai F, Gulley JL, Dahut WL, Wood BJ, Chang R, Levy E, Choyke PL, Lindenberg L. A Comparison of (18)F-DCFPyL, (18)F-NaF, and (18)F-FDG PET/CT in a Prospective Cohort of Men with Metastatic Prostate Cancer. *J Nucl Med.* 2022;63(5):735-41.
18. Chen MS, Lee RJ, **Madan, RA**, Ta Park V, Shinagawa SM, Sun T, Gomez SL. Charting a Path Towards Asian American Cancer Health Equity: A Way Forward. *J Natl Cancer Inst.* 2022;114(6):792-9.
19. Chandran E, Meininger L, Karzai F, **Madan, RA**. Signaling new therapeutic opportunities: cytokines in prostate cancer. *Expert Opin Biol Ther.* 2022;22(10):1233-43.
20. Chandran E, Figg WD, **Madan, R**. Lutetium-177-PSMA-617: A Vision of the Future. *Cancer Biol Ther.* 2022;23(1):186-90.
21. Bilusic M, Toney NJ, Donahue RN, Wroblewski S, Zibelman M, Ghatalia P, Ross EA, Karzai F, **Madan, RA**, Dahut WL, Gulley JL, Schlom J, Plimack ER, Geynisman DM. A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1). *Prostate Cancer Prostatic Dis.* 2022.
22. Wilkinson S, Ye H, Karzai F, Harmon SA, Terrigino NT, VanderWeele DJ, Bright JR, Atway R, Trostel SY, Carrabba NV, Whitlock NC, Walker SM, Lis RT, Abdul Sater H, Capaldo BJ, **Madan, RA**, Gulley JL, Chun G, Merino MJ, Pinto PA, Salles DC, Kaur HB, Lotan TL, Venzon DJ, Choyke PL, Turkbey B, Dahut WL, Sowalsky AG. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. *Eur Urol.* 2021;80(6):746-57.
23. Masoudi S, Mehravivand S, Harmon SA, Lay N, Lindenberg L, Mena E, Pinto PA, Citrin DE, Gulley JL, Wood BJ, Dahut WL, **Madan, RA**, Bagci U, Choyke PL, Turkbey B. Deep Learning Based Staging of Bone Lesions From Computed Tomography Scans. *IEEE Access.* 2021;9:87531-42.
24. **Madan, RA**, Palena C. Behind the IL-8 ball in prostate cancer. *Nat Cancer.* 2021;2(8):775-6.

25. **Madan, RA**, Karzai FH, Al Harthy M, Petrylak DP, Kim JW, Arlen PM, Rosner I, Theoret MR, Cordes L, Bilusic M, Peer CJ, Dawson NA, Couvillon A, Hankin A, Williams M, Chun G, Owens H, Marte JL, Lee MJ, Tomita Y, Yuno A, Trepel JB, Lee S, Steinberg SM, Gulley JL, Figg WD, Dahut WL. Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer. *BJU Int.* 2021;127(4):435-44.
26. **Madan, RA**, Karzai F, Donahue RN, Al-Harthy M, Bilusic M, Rosner, II, Singh H, Arlen PM, Theoret MR, Marte JL, Cordes L, Couvillon A, Hankin A, Williams M, Owens H, Lochrin SE, Chau CH, Steinberg S, Figg WD, Dahut W, Schlom J, Gulley JL. Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer. *J Immunother Cancer.* 2021;9(3).
27. Lochrin SE, Turkbey B, Gasmi B, Schmidt K, Strobe JD, Chau CH, Sissung TM, Price DK, Cordes L, Markolovic S, Wood BJ, Pinto PA, McKinney YL, Shih JH, Levy E, **Madan, R**, Dahut W, Choyke PL, Merino M, Figg WD. Pilot study of gadoxetate disodium-enhanced mri for localized and metastatic prostate cancers. *Sci Rep.* 2021;11(1):5662.
28. Lee RJ, **Madan, RA**, Kim J, Posadas EM, Yu EY. Disparities in Cancer Care and the Asian American Population. *Oncologist.* 2021;26(6):453-60.
29. Karzai F, Walker SM, Wilkinson S, **Madan, RA**, Shih JH, Merino MJ, Harmon SA, VanderWeele DJ, Cordes LM, Carrabba NV, Bright JR, Terrigino NT, Chun G, Bilusic M, Couvillon A, Hankin A, Williams MN, Lis RT, Ye H, Choyke PL, Gulley JL, Sowalsky AG, Turkbey B, Pinto PA, Dahut WL. Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response. *Clin Cancer Res.* 2021;27(2):429-37.
30. Gubbi S, Cordes LM, Klubo-Gwiezdzinska J, **Madan, RA**, Nieman LK, Gulley JL, Del Rivero J. In Reply. *Oncologist.* 2021;26(1):e192-e3.
31. DeMaria PJ, Lee-Wisdom K, Donahue RN, **Madan, RA**, Karzai F, Schwab A, Palena C, Jochems C, Floudas C, Strauss J, Marte JL, Redman JM, Dombi E, Widemann B, Korchin B, Adams T, Pico-Navarro C, Heery C, Schlom J, Gulley JL, Bilusic M. Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer. *J Immunother Cancer.* 2021;9(9).
32. DeMaria PJ, Bilusic M, Park DM, Heery CR, Donahue RN, **Madan, RA**, Bagheri MH, Strauss J, Shen V, Marte JL, Steinberg SM, Schlom J, Gilbert MR, Gulley JL. Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma. *Oncologist.* 2021;26(5):e847-e58.
33. Cordes LM, Schmidt KT, Peer CJ, Chau CH, Redmond E, Francis D, Karzai F, **Madan, RA**, Figg WD. Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single-Dose Administration Under Fasting Conditions in Prostate Cancer. *Oncologist.* 2021;26(9):729-e1493.
34. Chau V, **Madan, RA**, Bilusic M, Owens H, Cordes LM, Marte JL, Gulley JL, Lee JM, Dahut WL, Karzai F. Anaplastic Features in Advanced Prostate Cancer With and Without DNA Damage Repair Mutations. *Clin Genitourin Cancer.* 2021;19(6):e352-e9.
35. Chau V, **Madan, RA**, Aragon-Ching JB. Protein kinase inhibitors for the treatment of prostate cancer. *Expert Opin Pharmacother.* 2021;22(14):1889-99.
36. Bilusic M, McMahon S, **Madan, RA**, Karzai F, Tsai YT, Donahue RN, Palena C, Jochems C, Marte JL, Floudas C, Strauss J, Redman J, Abdul Sater H, Rabizadeh S, Soon-Shiong P, Schlom J, Gulley JL. Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC). *J Immunother Cancer.* 2021;9(3).
37. Wilkinson S, Harmon SA, Terrigino NT, Karzai F, Pinto PA, **Madan, RA**, VanderWeele DJ, Lake R, Atway R, Bright JR, Carrabba NV, Trostel SY, Lis RT, Chun G, Gulley JL, Merino MJ, Choyke PL, Ye H, Dahut WL, Turkbey B, Sowalsky AG. A case report of multiple primary prostate tumors with differential drug sensitivity. *Nat Commun.* 2020;11(1):837.
38. Turkbey B, Czarniecki M, Shih JH, Harmon SA, Agarwal PK, Apolo AB, Citrin DE, Gulley JL, Harisinghani M, **Madan, RA**, Metwalli AR, Paquette E, Pinto PA, Rais-Bahrami S, Rowe LS, Wood BJ, Jacobs

- PM, Lindenberg L, Dahut W, Choyke PL. Ferumoxytol-Enhanced MR Lymphography for Detection of Metastatic Lymph Nodes in Genitourinary Malignancies: A Prospective Study. *AJR Am J Roentgenol*. 2020;214(1):105-13.
39. Strauss J, Gatti-Mays ME, Cho BC, Hill A, Salas S, McClay E, Redman JM, Sater HA, Donahue RN, Jochems C, Lamping E, Burmeister A, Marte JL, Cordes LM, Bilusic M, Karzai F, Ojalvo LS, Jehl G, Rolfe PA, Hinrichs CS, **Madan, RA**, Schlom J, Gulley JL. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with human papillomavirus-associated malignancies. *J Immunother Cancer*. 2020;8(2).
40. Schmidt KT, Peer CJ, Huitema ADR, Williams MD, Wroblewski S, Schellens JHM, **Madan, RA**, Figg WD. Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma. *J Pharm Biomed Anal*. 2020;181:113073.
41. Schmidt KT, Huitema ADR, Dorlo TPC, Peer CJ, Cordes LM, Sciuto L, Wroblewski S, Pommier Y, **Madan, RA**, Thomas A, Figg WD. Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors. *Cancer Chemother Pharmacol*. 2020;86(4):475-86.
42. S UG, **Madan, RA**, Aragon-Ching JB. The immunotherapy revolution in genitourinary malignancies. *Immunotherapy*. 2020;12(11):819-31.
43. **Madan, RA**, Schmidt KT, Karzai F, Peer CJ, Cordes LM, Chau CH, Steinberg SM, Owens H, Eisner J, Moore WR, Dahut WL, Gulley JL, Figg WD. Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment. *Clin Genitourin Cancer*. 2020;18(4):258-67 e1.
44. **Madan, RA**, Antonarakis ES, Drake CG, Fong L, Yu EY, McNeel DG, Lin DW, Chang NN, Sheikh NA, Gulley JL. Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. *J Natl Cancer Inst*. 2020;112(6):562-73.
45. Lindenberg L, Mena E, Turkbey B, Shih JH, Reese SE, Harmon SA, Lim I, Lin F, Ton A, McKinney YL, Eclarinal P, Citrin DE, Dahut W, **Madan, R**, Wood BJ, Krishnasamy V, Chang R, Levy E, Pinto P, Eary JF, Choyke PL. Evaluating Biochemically Recurrent Prostate Cancer: Histologic Validation of (18)F-DCFPyL PET/CT with Comparison to Multiparametric MRI. *Radiology*. 2020;296(3):564-72.
46. Karzai F, **Madan, RA**, Dahut WL. The World of Clinical Trial Development Post COVID-19: Lessons Learned from a Global Pandemic. *Clin Cancer Res*. 2020;26(16):4198-200.
47. Karzai F, **Madan, RA**, Dahut WL. How Do We Respond to Men with BRCA Mutations when They Ask About Prostate Cancer? *Eur Urol*. 2020;77(1):36-7.
48. Gatti-Mays ME, Redman JM, Donahue RN, Palena C, **Madan, RA**, Karzai F, Bilusic M, Sater HA, Marte JL, Cordes LM, McMahon S, Steinberg SM, Orpia A, Burmeister A, Schlom J, Gulley JL, Strauss J. A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer. *Oncologist*. 2020;25(6):479-e899.
49. Del Rivero J, Donahue RN, Marte JL, Gramza AW, Bilusic M, Rauckhorst M, Cordes L, Merino MJ, Dahut WL, Schlom J, Gulley JL, **Madan, RA**. A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer. *Front Endocrinol (Lausanne)*. 2020;11:490.
50. Del Rivero J, Cordes LM, Klubo-Gwiedzinska J, **Madan, RA**, Nieman LK, Gulley JL. Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management. *Oncologist*. 2020;25(4):290-300.
51. Collins JM, Donahue RN, Tsai YT, Manu M, Palena C, Gatti-Mays ME, Marte JL, **Madan, RA**, Karzai F, Heery CR, Strauss J, Abdul-Sater H, Cordes L, Schlom J, Gulley JL, Bilusic M. Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors. *Oncologist*. 2020;25(7):560-e1006.

52. Chau V, **Madan, RA**, Figg WD. Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer. *Cancer Biol Ther.* 2020;21(10):884-7.
53. Bilusic M, Einstein DJ, Karzai FH, Dahut WL, Gulley JL, Aragon-Ching JB, **Madan, RA**. The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer. *Urol Clin North Am.* 2020;47(4):457-67.
54. Aragon-Ching JB, **Madan, RA**. Life under the CABOSUN: Cabozantinib improves quality-adjusted survival in comparison with sunitinib. *Cancer.* 2020;126(24):5210-2.
55. Alyamani M, Li J, Patel M, Taylor S, Nakamura F, Berk M, Przybycin C, Posadas EM, **Madan, RA**, Gulley JL, Rini B, Garcia JA, Klein EA, Sharifi N. Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure. *Ann Oncol.* 2020;31(3):369-76.
56. Al Harthy M, Redman J, **Madan, RA**. Novel immunotherapy combinations for genitourinary cancers. *Expert Opin Biol Ther.* 2020;20(3):253-62.
57. Abdul Sater H, Marte JL, Donahue RN, Walter-Rodriguez B, Heery CR, Steinberg SM, Cordes LM, Chun G, Karzai F, Bilusic M, Harmon SA, Turkbey IB, Choyke PL, Schlom J, Dahut WL, **Madan, RA**, Pinto PA, Gulley JL. Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer. *J Immunother Cancer.* 2020;8(1).
58. Warner BM, Baer AN, Lipson EJ, Allen C, Hinrichs C, Rajan A, Pelayo E, Beach M, Gulley JL, **Madan, RA**, Feliciano J, Grisius M, Long L, Powers A, Kleiner DE, Cappelli L, Alevizos I. Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. *Oncologist.* 2019;24(9):1259-69.
59. Strauss J, Heery CR, Kim JW, Jochems C, Donahue RN, Montgomery AS, McMahon S, Lamping E, Marte JL, **Madan, RA**, Bilusic M, Silver MR, Bertotti E, Schlom J, Gulley JL. First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors. *Clin Cancer Res.* 2019;25(1):99-109.
60. Redman JM, Rhea LP, Cordes L, Owens H, **Madan, RA**, Bilusic M, Gulley JL, Lee JM, Dahut WL, Karzai F. A Case of Anti-PD-L1-associated Remitting Seronegative Symmetric Synovitis With Pitting Edema. *Clin Genitourin Cancer.* 2019;17(3):e549-e52.
61. Rajan A, Heery CR, Thomas A, Mammen AL, Perry S, O'Sullivan Coyne G, Guha U, Berman A, Szabo E, **Madan, RA**, Ballester LY, Pittaluga S, Donahue RN, Tsai YT, Lepone LM, Chin K, Ginty F, Sood A, Hewitt SM, Schlom J, Hassan R, Gulley JL. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. *J Immunother Cancer.* 2019;7(1):269.
62. Peer CJ, Schmidt KT, Kindrick JD, Eisner JR, Brown VV, Baskin-Bey E, **Madan, R**, Figg WD. A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer. *Cancer Chemother Pharmacol.* 2019;84(4):759-70.
63. **Madan, RA**, Gulley JL. Finding an Immunologic Beachhead in the Prostate Cancer Microenvironment. *J Natl Cancer Inst.* 2019;111(3):219-20.
64. Gold SA, VanderWeele DJ, Harmon S, Bloom JB, Karzai F, Hale GR, Marhamati S, Rayn KN, Mehralivand S, Merino MJ, Gulley JL, Bilusic M, **Madan, RA**, Choyke PL, Turkbey B, Dahut W, Pinto PA. mpMRI preoperative staging in men treated with antiandrogen and androgen deprivation therapy before robotic prostatectomy. *Urol Oncol.* 2019;37(6):352 e25- e30.
65. Gatti-Mays ME, Strauss J, Donahue RN, Palena C, Del Rivero J, Redman JM, **Madan, RA**, Marte JL, Cordes LM, Lamping E, Orpia A, Burmeister A, Wagner E, Pico Navarro C, Heery CR, Schlom J, Gulley JL. A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules. *Clin Cancer Res.* 2019;25(16):4933-44.

66. Del Rivero J, Edgerly M, Ward J, **Madan, RA**, Balasubramaniam S, Fojo T, Gramza AW. Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer. *Oncologist*. 2019;24(1):16-e4.
67. Bilusic M, Heery CR, Collins JM, Donahue RN, Palena C, **Madan, RA**, Karzai F, Marte JL, Strauss J, Gatti-Mays ME, Schlom J, Gulley JL. Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. *J Immunother Cancer*. 2019;7(1):240.
68. Strauss J, Heery CR, Schlom J, **Madan, RA**, Cao L, Kang Z, Lamping E, Marte JL, Donahue RN, Grenga I, Cordes L, Christensen O, Mahnke L, Helwig C, Gulley JL. Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFbeta, in Advanced Solid Tumors. *Clin Cancer Res*. 2018;24(6):1287-95.
69. Schmidt KT, **Madan, RA**, Figg WD. Expanding the use of abiraterone in prostate cancer: Is earlier always better? *Cancer Biol Ther*. 2018;19(2):97-100.
70. Redman JM, **Madan, RA**. Spotlight on atezolizumab and its potential as an oncology agent. *Expert Rev Anticancer Ther*. 2018;18(8):719-22.
71. Pezaro CJ, Marciscano AE, **Madan, RA**. The Winds of Change: Emerging Therapeutics in Prostate Cancer. *Am Soc Clin Oncol Educ Book*. 2018;38:382-90.
72. Parsons JK, Pinto PA, Pavlovich CP, Uchio E, Kim HL, Nguyen MN, Gulley JL, Jamieson C, Hsu P, Wojtowicz M, Parnes H, Schlom J, Dahut WL, **Madan, RA**, Donahue RN, Chow HS. A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study. *Eur Urol Focus*. 2018;4(5):636-8.
73. Marciscano AE, **Madan, RA**. Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies. *Curr Treat Options Oncol*. 2018;19(3):16.
74. **Madan, RA**, Gulley JL. Pembrolizumab: patient selection or immune intensification? *Nat Rev Urol*. 2018;15(10):593-4.
75. Karzai F, VanderWeele D, **Madan, RA**, Owens H, Cordes LM, Hankin A, Couvillon A, Nichols E, Bilusic M, Beshiri ML, Kelly K, Krishnasamy V, Lee S, Lee MJ, Yuno A, Trepel JB, Merino MJ, Dittamore R, Marte J, Donahue RN, Schlom J, Killian KJ, Meltzer PS, Steinberg SM, Gulley JL, Lee JM, Dahut WL. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. *J Immunother Cancer*. 2018;6(1):141.
76. Harmon SA, Mena E, Shih JH, Adler S, McKinney Y, Bergvall E, Mehralivand S, Sowalsky AG, Couvillon A, **Madan, RA**, Gulley JL, Eary J, Mease RC, Pomper MG, Dahut WL, Turkbey B, Lindenberg L, Choyke PL. A comparison of prostate cancer bone metastases on (18)F-Sodium Fluoride and Prostate Specific Membrane Antigen ((18)F-PSMA) PET/CT: Discordant uptake in the same lesion. *Oncotarget*. 2018;9(102):37676-88.
77. Harmon SA, Bergvall E, Mena E, Shih JH, Adler S, McKinney Y, Mehralivand S, Citrin DE, Couvillon A, **Madan, RA**, Gulley JL, Mease RC, Jacobs PM, Pomper MG, Turkbey B, Choyke PL, Lindenberg ML. A Prospective Comparison of (18)F-Sodium Fluoride PET/CT and PSMA-Targeted (18)F-DCFBC PET/CT in Metastatic Prostate Cancer. *J Nucl Med*. 2018;59(11):1665-71.
78. Cordes LM, Gulley JL, **Madan, RA**. Perspectives on the clinical development of immunotherapy in prostate cancer. *Asian J Androl*. 2018;20(3):253-9.
79. Aragon-Ching JB, **Madan, RA**. The path forward in prostate cancer therapeutics. *Asian J Androl*. 2018;20(3):213-4.
80. Roman JW, Ojemuyiwa MA, Cordes LM, **Madan, RA**, Sperling L. Docetaxel extravasation: Pathologic correlation and treatment with intralesional steroids. *JAAD Case Rep*. 2017;3(4):322-5.
81. Redman JM, Gulley JL, **Madan, RA**. Combining immunotherapies for the treatment of prostate cancer. *Urol Oncol*. 2017;35(12):694-700.

82. **Madan, RA**, Gulley JL. Prostate cancer immunotherapy: the path forward. *Curr Opin Support Palliat Care*. 2017;11(3):225-30.
83. **Madan, RA**, Gulley JL. Prostate cancer: Better VISTAs ahead? Potential and pitfalls of immunotherapy. *Nat Rev Urol*. 2017;14(8):455-6.
84. Heery CR, Palena C, McMahon S, Donahue RN, Lepone LM, Grenga I, Dirmeier U, Cordes L, Marte J, Dahut W, Singh H, **Madan, RA**, Fernando RI, Hamilton DH, Schlom J, Gulley JL. Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury. *Clin Cancer Res*. 2017;23(22):6833-45.
85. Heery CR, O'Sullivan-Coyne G, **Madan, RA**, Cordes L, Rajan A, Rauckhorst M, Lamping E, Oyelakin I, Marte JL, Lepone LM, Donahue RN, Grenga I, Cuillerot JM, Neuteboom B, Heydebreck AV, Chin K, Schlom J, Gulley JL. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. *Lancet Oncol*. 2017;18(5):587-98.
86. Gulley JL, **Madan, RA**, Pachynski R, Mulders P, Sheikh NA, Trager J, Drake CG. Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. *J Natl Cancer Inst*. 2017;109(4).
87. Fakhrejehani F, **Madan, RA**, Dahut WL. Management Options for Biochemically Recurrent Prostate Cancer. *Curr Treat Options Oncol*. 2017;18(5):26.
88. Donahue RN, Lepone LM, Grenga I, Jochems C, Fantini M, **Madan, RA**, Heery CR, Gulley JL, Schlom J. Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody. *J Immunother Cancer*. 2017;5:20.
89. Burotto M, Edgerly M, Velarde M, Balasubramaniam S, Drabkin H, Gormaz JG, O'Sullivan C, **Madan, R**, Fojo T. A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma. *Oncologist*. 2017;22(8):888-e84.
90. Bilusic M, **Madan, RA**, Gulley JL. Immunotherapy of Prostate Cancer: Facts and Hopes. *Clin Cancer Res*. 2017;23(22):6764-70.
91. Apolo AB, Karzai FH, Trepel JB, Alarcon S, Lee S, Lee MJ, Tomita Y, Cao L, Yu Y, Merino MJ, **Madan, RA**, Parnes HL, Steinberg SM, Rodriguez BW, Seon BK, Gulley JL, Arlen PM, Dawson NA, Figg WD, Dahut WL. A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma. *Clin Genitourin Cancer*. 2017;15(1):77-85.
92. Wood LV, Fojo A, Roberson BD, Hughes MS, Dahut W, Gulley JL, **Madan, RA**, Arlen PM, Sabatino M, Stroncek DF, Castiello L, Trepel JB, Lee MJ, Parnes HL, Steinberg SM, Terabe M, Wilkerson J, Pastan I, Berzofsky JA. TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer. *Oncoimmunology*. 2016;5(8):e1197459.
93. Wattenberg MM, Fong L, **Madan, RA**, Gulley JL. Immunotherapy in genitourinary malignancies. *Curr Opin Urol*. 2016;26(6):501-7.
94. Strauss J, **Madan, RA**, Gulley JL. Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors. *Expert Opin Biol Ther*. 2016;16(7):895-901.
95. Strauss J, **Madan, RA**. Therapeutic vaccines for prostate cancer: recent advances and future directions. *Expert Rev Vaccines*. 2016;15(7):907-14.
96. McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, Kantoff PW, **Madan, RA**, Oh WK, Peace DJ, Petrylak DP, Porterfield H, Sartor O, Shore ND, Slovin SF, Stein MN, Vieweg J, Gulley JL. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. *J Immunother Cancer*. 2016;4:92.
97. **Madan, RA**, Karzai FH, Ning YM, Adesunloye BA, Huang X, Harold N, Couvillon A, Chun G, Cordes L, Sissung T, Beedie SL, Dawson NA, Theoret MR, McLeod DG, Rosner I, Trepel JB, Lee MJ, Tomita Y, Lee S, Chen C, Steinberg SM, Arlen PM, Gulley JL, Figg WD, Dahut WL. Phase II trial of docetaxel,

bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer. *BJU Int.* 2016;118(4):590-7.

98. **Madan, RA**, Gulley JL, Dahut WL. Radium-223 in prostate cancer: emitting the right signals. *Lancet Oncol.* 2016;17(9):1186-7.

99. **Madan, RA**, Gulley JL. Prospects for the future of prostate cancer vaccines. *Expert Rev Vaccines.* 2016;15(3):271-4.

100. Lepone LM, Donahue RN, Grenga I, Metenou S, Richards J, Heery CR, **Madan, RA**, Gulley JL, Schlom J. Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types. *J Circ Biomark.* 2016;5:5.

101. Karzai FH, **Madan, RA**, Dahut WL. Metabolic syndrome in prostate cancer: impact on risk and outcomes. *Future Oncol.* 2016;12(16):1947-55.

102. Jochems C, Fantini M, Fernando RI, Kwilas AR, Donahue RN, Lepone LM, Grenga I, Kim YS, Brechbiel MW, Gulley JL, **Madan, RA**, Heery CR, Hodge JW, Newton R, Schlom J, Tsang KY. The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells. *Oncotarget.* 2016;7(25):37762-72.

103. Heery CR, **Madan, RA**, Stein MN, Stadler WM, Di Paola RS, Rauckhorst M, Steinberg SM, Marte JL, Chen CC, Grenga I, Donahue RN, Jochems C, Dahut WL, Schlom J, Gulley JL. Samarium-153-EDTMP (Quadramet(R)) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial. *Oncotarget.* 2016;7(42):69014-23.

104. Gulley JL, **Madan, RA**. Developing immunotherapy strategies in the treatment of prostate cancer. *Asian J Urol.* 2016;3(4):278-85.

105. Farsaci B, Donahue RN, Grenga I, Lepone LM, Kim PS, Dempsey B, Siebert JC, Ibrahim NK, **Madan, RA**, Heery CR, Gulley JL, Schlom J. Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. *Cancer Immunol Res.* 2016;4(9):755-65.

106. Cordes LM, Gulley JL, **Madan, RA**. The evolving role of immunotherapy in prostate cancer. *Curr Opin Oncol.* 2016;28(3):232-40.

107. Apolo AB, Lindenberg L, Shih JH, Mena E, Kim JW, Park JC, Alikhani A, McKinney YY, Weaver J, Turkbey B, Parnes HL, Wood LV, **Madan, RA**, Gulley JL, Dahut WL, Kurdziel KA, Choyke PL. Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer. *J Nucl Med.* 2016;57(6):886-92.

108. Strauss J, **Madan, RA**, Figg WD. Evaluating immune responses after sipuleucel-T therapy. *Cancer Biol Ther.* 2015;16(8):1119-21.

109. Strauss J, **Madan, RA**. Integrating Immunotherapies in Prostate Cancer. *Curr Oncol Rep.* 2015;17(10):45.

110. McNeel DG, Chen YH, Gulley JL, Dwyer AJ, **Madan, RA**, Carducci MA, DiPaola RS. Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809). *Hum Vaccin Immunother.* 2015;11(10):2469-74.

111. **Madan, RA**, Gulley JL. Moving the goal posts in prostate cancer trials. *Lancet Oncol.* 2015;16(3):247-9.

112. **Madan, RA**, Gulley JL. (R)Evolutionary therapy: the potential of immunotherapy to fulfill the promise of personalized cancer treatment. *J Natl Cancer Inst.* 2015;107(1):347.

113. **Madan, RA**, Dahut WL. Prostate cancer: Charting a course in metastatic castration-sensitive prostate cancer. *Nat Rev Urol.* 2015;12(7):368-9.

114. **Madan, R**, Dahut WL. Abiraterone's efficacy confirmed; time to aim higher. *Lancet Oncol.* 2015;16(2):119-21.
115. Lu D, Graf RP, Harvey M, **Madan, RA**, Heery C, Marte J, Beasley S, Tsang KY, Krupa R, Louw J, Wahl J, Bales N, Landers M, Marrinucci D, Schlom J, Gulley JL, Dittamore R. Detection and Characterization of Circulating Tumour Cells from Frozen Peripheral Blood Mononuclear Cells. *J Circ Biomark.* 2015;4:4.
116. Karzai FH, **Madan, RA**, Figg WD. Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer. *South Med J.* 2015;108(4):224-8.
117. Karzai FH, Apolo AB, Cao L, **Madan, RA**, Adelberg DE, Parnes H, McLeod DG, Harold N, Peer C, Yu Y, Tomita Y, Lee MJ, Lee S, Trepel JB, Gulley JL, Figg WD, Dahut WL. A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer. *BJU Int.* 2015;116(4):546-55.
118. Heery CR, Singh BH, Rauckhorst M, Marte JL, Donahue RN, Grenga I, Rodell TC, Dahut W, Arlen PM, **Madan, RA**, Schlom J, Gulley JL. Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury. *Cancer Immunol Res.* 2015;3(11):1248-56.
119. Heery CR, Ibrahim NK, Arlen PM, Mohebtash M, Murray JL, Koenig K, **Madan, RA**, McMahon S, Marte JL, Steinberg SM, Donahue RN, Grenga I, Jochems C, Farsaci B, Folio LR, Schlom J, Gulley JL. Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial. *JAMA Oncol.* 2015;1(8):1087-95.
120. Gulley JL, Marte J, Heery CR, **Madan, RA**, Steinberg SM, Leitman SF, Tsang KY, Schlom J. The impact of leukapheresis on immune-cell number and function in patients with advanced cancer. *Cancer Immunol Immunother.* 2015;64(11):1429-35.
121. Gabitzsch ES, Tsang KY, Palena C, David JM, Fantini M, Kwilas A, Rice AE, Latchman Y, Hodge JW, Gulley JL, **Madan, RA**, Heery CR, Balint JP, Jr., Jones FR, Schlom J. The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic. *Oncotarget.* 2015;6(31):31344-59.
122. Yavuz S, Apolo AB, Kummar S, del Rivero J, **Madan, RA**, Shawker T, Reynolds J, Celi FS. Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma. *Thyroid.* 2014;24(8):1223-31.
123. Surolia I, Gulley J, **Madan, RA**. Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies. *Expert Opin Biol Ther.* 2014;14(12):1769-81.
124. Sternberg CN, Petrylak DP, **Madan, RA**, Parker C. Progress in the treatment of advanced prostate cancer. *Am Soc Clin Oncol Educ Book.* 2014:117-31.
125. Schlom J, Hodge JW, Palena C, Tsang KY, Jochems C, Greiner JW, Farsaci B, **Madan, RA**, Heery CR, Gulley JL. Therapeutic cancer vaccines. *Adv Cancer Res.* 2014;121:67-124.
126. Ojemuyiwa MA, **Madan, RA**, Dahut WL. Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development. *Expert Opin Emerg Drugs.* 2014;19(4):459-70.
127. O'Sullivan Coyne G, **Madan, RA**, Gulley JL. Nivolumab: promising survival signal coupled with limited toxicity raises expectations. *J Clin Oncol.* 2014;32(10):986-8.
128. **Madan, RA**, Heery CR, Gulley JL. Poxviral-based vaccine elicits immunologic responses in prostate cancer patients. *Oncoimmunology.* 2014;3:e28611.
129. Jochems C, Tucker JA, Tsang KY, **Madan, RA**, Dahut WL, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. *Cancer Immunol Immunother.* 2014;63(4):407-18.
130. Gulley JL, **Madan, RA**, Tsang KY, Jochems C, Marte JL, Farsaci B, Tucker JA, Hodge JW, Liewehr DJ, Steinberg SM, Heery CR, Schlom J. Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. *Cancer Immunol Res.* 2014;2(2):133-41.



131. Farsaci B, Jochems C, Grenga I, Donahue RN, Tucker JA, Pinto PA, Merino MJ, Heery CR, **Madan, RA**, Gulley JL, Schlom J. Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets. *Int J Cancer*. 2014;135(4):862-70.
132. Dahut WL, **Madan, RA**. Real-world experience with abiraterone. *Lancet Oncol*. 2014;15(11):1188-90.
133. Burotto M, Singh N, Heery CR, Gulley JL, **Madan, RA**. Exploiting synergy: immune-based combinations in the treatment of prostate cancer. *Front Oncol*. 2014;4:351.
134. Bilusic M, Heery CR, Arlen PM, Rauckhorst M, Apelian D, Tsang KY, Tucker JA, Jochems C, Schlom J, Gulley JL, **Madan, RA**. Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. *Cancer Immunol Immunother*. 2014;63(3):225-34.
135. Singh N, **Madan, RA**, Gulley JL. Ipilimumab in prostate cancer. *Expert Opin Biol Ther*. 2013;13(2):303-13.
136. **Madan, RA**, Tsang KY, Bilusic M, Vergati M, Poole DJ, Jochems C, Tucker JA, Schlom J, Giaccone G, Gulley JL. Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer. *Oncologist*. 2013;18(7):821-2.
137. **Madan, RA**, Shah AA, Dahut WL. Is it time to reevaluate definitive therapy in prostate cancer? *J Natl Cancer Inst*. 2013;105(10):683-5.
138. **Madan, RA**, Gulley JL, Kantoff PW. Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. *Cancer J*. 2013;19(1):50-8.
139. **Madan, RA**, Gulley JL. Prostate cancer: Intermediate efficacy end points to assess modern therapies. *Nat Rev Urol*. 2013;10(12):686-7.
140. **Madan, RA**, Arlen PM. Recent advances revolutionize treatment of metastatic prostate cancer. *Future Oncol*. 2013;9(8):1133-44.
141. Huen NY, Pang AL, Tucker JA, Lee TL, Vergati M, Jochems C, Intrivici C, Cereda V, Chan WY, Rennert OM, **Madan, RA**, Gulley JL, Schlom J, Tsang KY. Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer. *Int J Cancer*. 2013;133(2):373-82.
142. Huang J, Jochems C, Anderson AM, Talaie T, Jales A, **Madan, RA**, Hodge JW, Tsang KY, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J. Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity. *J Immunol*. 2013;190(12):6250-8.
143. Gulley JL, **Madan, RA**, Heery CR. Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical applications. *Am Soc Clin Oncol Educ Book*. 2013.
144. Gulley JL, Heery CR, **Madan, RA**, Walter BA, Merino MJ, Dahut WL, Tsang KY, Schlom J, Pinto PA. Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer. *Cancer Immunol Immunother*. 2013;62(9):1521-31.
145. Figg WD, Chau CH, **Madan, RA**, Gulley JL, Gao R, Sissung TM, Spencer S, Beatson M, Aragon-Ching J, Steinberg SM, Dahut WL. Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity. *Clin Genitourin Cancer*. 2013;11(3):229-37.
146. Dahut WL, **Madan, RA**, Karakunnel JJ, Adelberg D, Gulley JL, Turkbey IB, Chau CH, Spencer SD, Mulquin M, Wright J, Parnes HL, Steinberg SM, Choyke PL, Figg WD. Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. *BJU Int*. 2013;111(8):1269-80.
147. Sonpavde G, Di Lorenzo G, Higano CS, Kantoff PW, **Madan, R**, Shore ND. The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. *Eur Urol*. 2012;61(4):639-47.

148. **Madan, RA**, Schwaab T, Gulley JL. Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer. *J Natl Compr Canc Netw*. 2012;10(12):1505-12.
149. **Madan, RA**, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, Dahut WL, Schlom J, Gulley JL. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. *Lancet Oncol*. 2012;13(5):501-8.
150. **Madan, RA**, Heery CR, Gulley JL. Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity. *Oncoimmunology*. 2012;1(7):1167-8.
151. **Madan, RA**, Bilusic M, Heery C, Schlom J, Gulley JL. Clinical evaluation of TRICOM vector therapeutic cancer vaccines. *Semin Oncol*. 2012;39(3):296-304.
152. Kurdziel KA, Shih JH, Apolo AB, Lindenberg L, Mena E, McKinney YY, Adler SS, Turkbey B, Dahut W, Gulley JL, **Madan, RA**, Landgren O, Choyke PL. The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology. *J Nucl Med*. 2012;53(8):1175-84.
153. Kim JW, **Madan, RA**, Gulley JL. Initial PSA oscillations precede prolonged stable disease in a patient treated with a therapeutic cancer vaccine. *Clin Genitourin Cancer*. 2012;10(1):43-6.
154. Kim JW, Bilusic M, Heery CJ, **Madan, RA**. Therapeutic cancer vaccines in prostate cancer: the quest for intermediate markers of response. *Cancers (Basel)*. 2012;4(4):1229-46.
155. Kamrava M, Kesarwala AH, **Madan, RA**, Lita E, Kaushal A, Tsang KY, Poole DJ, Steinberg SM, Ferrara T, Dahut W, Schlom J, Gulley JL. Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy. *Prostate Cancer Prostatic Dis*. 2012;15(3):289-95.
156. Huang J, Jochems C, Talaie T, Anderson A, Jales A, Tsang KY, **Madan, RA**, Gulley JL, Schlom J. Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. *Blood*. 2012;120(15):3030-8.
157. Bilusic M, **Madan, RA**. Therapeutic cancer vaccines: the latest advancement in targeted therapy. *Am J Ther*. 2012;19(6):e172-81.
158. Vergati M, Cereda V, **Madan, RA**, Gulley JL, Huen NY, Rogers CJ, Hance KW, Arlen PM, Schlom J, Tsang KY. Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. *Cancer Immunol Immunother*. 2011;60(2):197-206.
159. Stein WD, Gulley JL, Schlom J, **Madan, RA**, Dahut W, Figg WD, Ning YM, Arlen PM, Price D, Bates SE, Fojo T. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. *Clin Cancer Res*. 2011;17(4):907-17.
160. Mohebtash M, Tsang KY, **Madan, RA**, Huen NY, Poole DJ, Jochems C, Jones J, Ferrara T, Heery CR, Arlen PM, Steinberg SM, Pazdur M, Rauckhorst M, Jones EC, Dahut WL, Schlom J, Gulley JL. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. *Clin Cancer Res*. 2011;17(22):7164-73.
161. **Madan, RA**, Pal SK, Sartor O, Dahut WL. Overcoming chemotherapy resistance in prostate cancer. *Clin Cancer Res*. 2011;17(12):3892-902.
162. **Madan, RA**, Gulley JL. Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer. *Expert Rev Vaccines*. 2011;10(2):141-50.
163. **Madan, RA**, Gulley JL. Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer. *Immunotherapy*. 2011;3(1):27-31.
164. **Madan, RA**, Aragon-Ching JB, Gulley JL, Dahut WL. From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. *Expert Rev Vaccines*. 2011;10(6):743-53.

165. Gulley JL, **Madan, RA**, Tsang KY, Arlen PM, Camphausen K, Mohebtash M, Kamrava M, Schlom J, Citrin D. A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver. *Expert Opin Biol Ther.* 2011;11(11):1409-18.
166. Gulley JL, **Madan, RA**, Schlom J. Impact of tumour volume on the potential efficacy of therapeutic vaccines. *Curr Oncol.* 2011;18(3):e150-7.
167. Bilusic M, Heery C, **Madan, RA**. Immunotherapy in prostate cancer: emerging strategies against a formidable foe. *Vaccine.* 2011;29(38):6485-97.
168. Zhu W, Zhu DS, **Madan, RA**, Gulley JL, Figg WD, Dahut WL. Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway. *Am J Ther.* 2010;17(2):176-81.
169. Rotow J, Gameiro SR, **Madan, RA**, Gulley JL, Schlom J, Hodge JW. Vaccines as monotherapy and in combination therapy for prostate cancer. *Clin Transl Sci.* 2010;3(3):116-22.
170. Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, Parnes HL, Trepel JB, Lee MJ, Kim YS, Sun H, **Madan, RA**, Latham L, Jones E, Chen CC, Figg WD, Dahut WL. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. *J Clin Oncol.* 2010;28(12):2070-6.
171. **Madan, RA**, Mohebtash M, Schlom J, Gulley JL. Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. *Expert Opin Biol Ther.* 2010;10(1):19-28.
172. **Madan, RA**, Gulley JL, Fojo T, Dahut WL. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. *Oncologist.* 2010;15(9):969-75.
173. **Madan, RA**, Gulley JL. The current and emerging role of immunotherapy in prostate cancer. *Clin Genitourin Cancer.* 2010;8(1):10-6.
174. Gulley JL, Arlen PM, **Madan, RA**, Tsang KY, Pazdur MP, Skarupa L, Jones JL, Poole DJ, Higgins JP, Hodge JW, Cereda V, Vergati M, Steinberg SM, Halabi S, Jones E, Chen C, Parnes H, Wright JJ, Dahut WL, Schlom J. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. *Cancer Immunol Immunother.* 2010;59(5):663-74.
175. Dahut WL, **Madan, RA**. Revisiting the ultimate target of treatment for prostate cancer. *Lancet.* 2010;375(9724):1409-10.
176. Aragon-Ching JB, **Madan, RA**, Dahut WL. Angiogenesis inhibition in prostate cancer: current uses and future promises. *J Oncol.* 2010;2010:361836.
177. Mohebtash M, Gulley JL, **Madan, RA**, Ferrara T, Arlen PM. Cancer vaccines: current directions and perspectives in prostate cancer. *Curr Opin Mol Ther.* 2009;11(1):31-6.
178. **Madan, RA**, Dahut WL. Angiogenesis inhibition in the treatment of prostate cancer. *Anticancer Agents Med Chem.* 2009;9(10):1070-8.
179. **Madan, RA**, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostavac-VF: a vector-based vaccine targeting PSA in prostate cancer. *Expert Opin Investig Drugs.* 2009;18(7):1001-11.
180. Kamrava M, Tsang KY, **Madan, RA**, Kaushal A, Coleman CN, Gulley J. Long-term survival and PSA control with radiation and immunotherapy for node positive prostate cancer. *Clin Dev Immunol.* 2009;2009:363914.
181. Arlen PM, Mohebtash M, **Madan, RA**, Gulley JL. Promising novel immunotherapies and combinations for prostate cancer. *Future Oncol.* 2009;5(2):187-96.
182. Mohebtash M, **Madan, RA**, Gulley JL, Arlen PM. Therapeutic prostate cancer vaccines: a review of the latest developments. *Curr Opin Investig Drugs.* 2008;9(12):1296-301.

183. **Madan, RA**, Gulley JL, Schlom J, Steinberg SM, Liewehr DJ, Dahut WL, Arlen PM. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. *Clin Cancer Res.* 2008;14(14):4526-31.
184. **Madan, RA**, Xia Q, Chang VT, Oriscello RG, Kasimis B. A retrospective analysis of cardiovascular morbidity in metastatic hormone-refractory prostate cancer patients on high doses of the selective COX-2 inhibitor celecoxib. *Expert Opin Pharmacother.* 2007;8(10):1425-31.
185. **Madan, RA**, Lieberman R, Gulley JL, Dahut W, Arlen PM. Significant prostate-specific antigen (PSA) response to low-dose ketoconazole in a patient with non-metastatic androgen-independent prostate cancer (AIPC) and a review of the literature. *Am J Ther.* 2007;14(3):310-3.
186. **Madan, RA**, Chang VT, Dever LL. An uncommon presentation of HIV-related lymphoma. *AIDS Patient Care STDS.* 2007;21(7):443-6.
187. **Madan, RA**, Arlen PM, Gulley JL. PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. *Expert Opin Biol Ther.* 2007;7(4):543-54.
188. Gulley JL, **Madan, RA**, Arlen PM. Enhancing efficacy of therapeutic vaccinations by combination with other modalities. *Vaccine.* 2007;25 Suppl 2:B89-96.
189. Arlen PM, **Madan, RA**, Hodge JW, Schlom J, Gulley JL. Combining Vaccines with Conventional Therapies for Cancer. *Update Cancer Ther.* 2007;2(1):33-9.
190. Arlen PM, Gulley JL, **Madan, RA**, Hodge JW, Schlom J. Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. *Crit Rev Immunol.* 2007;27(5):451-62.
191. **Madan, RA**, Gulley JL, Arlen PM. PSA-based vaccines for the treatment of prostate cancer. *Expert Rev Vaccines.* 2006;5(2):199-209.
192. **Madan, RA**, Arlen PM. Abiraterone. *Cougar Biotechnology. IDrugs.* 2006;9(1):49-55.
193. **Madan, RA**, Chang VT, Yook C, Baddoura FK, Srinivas S, Kasimis B. Waldenstrom's macroglobulinemia evolving into acute lymphoblastic leukemia: a case report and a review of the literature. *Leukemia.* 2004;18(8):1433-5.
194. Goldberg SL, **Madan, RA**, Rowley SD, Pecora AL, Hsu JW, Tantravahi R. Myelodysplastic subclones in chronic myeloid leukemia: implications for imatinib mesylate therapy. *Blood.* 2003;101(2):781.

**Book Chapters (selected)**

1. Atiq M, **Madan RA**. "Immunotherapy for Metastatic Prostate Cancer." In: *Urologic Oncology*. Stratton, KL, Morgans, AK, Eds. Switzerland: Springer Nature, 2022.
2. Bander NH, van den Eertwegh A, Fong, LE, **Madan RA** McNeel, D, O'sullivan,G, Nguyen D, Santegoets S, Stam A, Suurs F, van de Ven R, Zambran. "Vaccines, Immunotherapies and Gene-Based Therapies" In: *Medical Treatment of Urologic Malignancies*. Stief C., Fizazi K, Evans CP, Eds. Lisbon: ICUD-EAU, 2015.
3. **Madan RA**, Dahut WL, "Prostate Cancer." In: *Bethesda Handbook of Clinical Oncology*, 4th ed. Abraham J, Gulley JL, Allegra CJ, eds. Philadelphia: Lippincott, Williams & Wilkins; 2014:191-207.
4. Adesunloye BA, **Madan RA**, "Prostate Cancer." In: *Bethesda Handbook of Clinical Oncology*, 4th ed. Abraham J, Gulley JL, Allegra CJ, eds. Philadelphia: Lippincott, Williams & Wilkins; 2014:218-232.
5. **Madan RA**, Ferrara TA, Gulley JL, "Therapeutic Cancer Vaccines: An Emerging Approach to Cancer" In: *Treatment Handbook of Anticancer Pharmacokinetics and Pharmacodynamics*, Springer Publications, *in press*.

6. Heery CR, Bilusic M, **Madan RA**. “Emerging treatment strategies for metastatic prostate cancer: the next step forward.” In: *Emerging Cancer Therapeutics*. Gulley J, Abraham J, eds. New York; Demos Medical Publishing; 2011:597-612.
7. Schlom J, **Madan RA**, Bilusic M, Heery CR, Hodge JW, Gulley JL. “Immune targeting of prostate cancer.” In: ASCO 2011 Genitourinary Cancers Symposium Education Book.
8. **Madan RA**, Gulley JL, Celestin J, Arlen PA, Schlom J. “Cancer immunology, immunotherapeutics and vaccine approaches.” In: *Drug Management of Prostate Cancer*. Figg W, Chau C, Small EJ, eds. New York: Springer; 2010:305-19.
9. **Madan RA**, Kramer BS. “Testicular carcinoma.” In: *Bethesda Handbook of Clinical Oncology*, 3<sup>rd</sup> ed. Abraham J, Gulley JL, Allegra CJ, eds. Philadelphia: Lippincott, Williams & Wilkins; 2010:210-230.
10. Aragon-Ching J, **Madan RA**, Gulley JL. “The clinical utility of bevacizumab.” In: *Angiogenesis: An Integrative Approach from Science to Medicine*. Figg W, Folkman J, eds. New York: Springer Science+Business Media; 2008:375-86.

### Honors and Awards

<b>Veterans Health Administration Office of Research and Development Exemplary Service and Leadership Award</b> For leadership in the scientific review of oncology studies and emergent review of COVID-19 initiatives	2/21
<b>Federal Technology Transfer Award</b> For outstanding work in the process of transferring federally developed technology	8/20
<b>U.S. Department of Health and Human Services Hubert H. Humphrey Award for Service to America</b>	5/19
<b>Federal Technology Transfer Award</b> For outstanding work in the process of transferring federally developed technology	8/19
<b>NCI Director’s Award of Merit</b> Expediting the Clinical Development of Avelumab From First-in-human studies to FDA Approval.	11/18
<b>Educational Institution and Federal Laboratory Partnership Award</b> NCI Immunology Fellowship co-sponsored by SITC	11/18
<b>Federal Technology Transfer Award</b> For outstanding work in the process of transferring federally developed technology	8/18
<b>Excellence in Technology Transfer Award</b> For clinical development of Avelumab in Metastatic Merkel Cell and Urothelial Carcinomas	4/18
<b>Federal Technology Transfer Award</b> For outstanding work in the process of transferring federally developed technology	8/17

<b>Federal Technology Transfer Award</b> For outstanding work in the process of transferring federally developed technology	8/16
<b>Prostate Cancer Young Investigator Award</b> Prostate Cancer Foundation	8/15
<b>Federal Technology Transfer Award</b> For outstanding work in the process of transferring federally developed technology	8/15
<b>Federal Technology Transfer Award</b> For outstanding work in the process of transferring federally developed technology	8/14
<b>Federal Technology Transfer Award</b> For outstanding work in the process of transferring federally developed technology	8/12
<b>NIH Merit Award</b> For great strides in prostate cancer research	11/11
<b>American Society of Clinical Oncology Merit Award</b> ASCO 2008 Annual Meeting, Chicago, IL	6/08
<b>American Society of Clinical Oncology Merit Award</b> ASCO Breast Cancer Symposium, San Francisco, CA	9/07
<b>American Society of Clinical Oncology Merit Award</b> ASCO Annual Meeting, Chicago, IL	6/07
<b>Department of Veterans Affairs Special Contribution Award for Unique Contribution to the Mission of the Department</b> East Orange (NJ) VA Hospital	1/05
<b>Award for Academic Achievement</b> UMDNJ – University Hospital	6/04

[Peer Reviewer Activity](#)

*Asian Journal of Andrology*  
*Cancer*  
*Cancer Cell*  
*Cancer Immunology, Immunotherapy*  
*Cancer Immunology Research*  
*Cancer Investigation*  
*Cancer Research*  
*Cellular and Molecular Life Sciences*  
*Clinical Investigation*  
*Clinical Cancer Research*  
*Clinical Genitourinary Cancer*  
*Expert Opinion on Biological Therapy*  
*Expert Opinion on Pharmacotherapy*  
*Expert Review of Clinical Pharmacology*  
*Expert Review of Vaccines*  
*European Urology*

*European Urology Oncology*  
*Genitourinary Malignancies*  
*Hospital Medicine*  
*International Journal of Cancer*  
*Immunotherapy*  
*Journal of Clinical Investigation*  
*Journal of Clinical Oncology*  
*JCO Clinical Practice*  
*Journal of Immunotherapy for Cancer*  
*Journal of the American Medical Association*  
*The Lancet*  
*Lancet Oncology*  
*Molecular Cancer Therapeutics*  
*Nature*  
*Nature Oncology*  
*Nature Reviews Urology*  
*Oncoimmunology*  
*Oncotarget*  
*Scientific Reports*  
*Technology in Cancer Research and Treatment*  
*Therapeutic Advances in Medical Oncology*  
*Urologic Oncology: Seminars and Original Investigations*